Landos Biopharma
Founded 2017 · CIK 0001785345 · Biotech · Acquired
LANCL2 agonist small molecule therapeutic (omilancor) for inflammatory bowel disease
landosbiopharma.com →- Grants
- $1.2M
- 2 awards
- Sector median: 1
- Raised
- $60M
- 1 Form D · Aug 2019
- 85 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 19 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $60,259,063 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · R01 · Phase 2 Proof-of-Concept Efficacy of BT-11 in Crohn's Disease Patients | $613,188 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · R01 · Phase 2 Proof-of-Concept Efficacy of BT-11 in Crohn's Disease Patients | $611,918 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2324 | Myricx Bio | — | — |
| 2325 | Abiologics | — | — |
| 2326 | APT THERAPEUTICS, INC. | — | — |
| 2327 | Landos Biopharma | — | $60M |
| 2328 | RESVITA BIO, INC. | — | — |
| 2329 | CALLENTIS CONSULTING GROUP LLC | — | — |
| 2330 | Protein Dynamic Solutions, Inc. | — | $3.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Josep Bassaganya-RieraDirector · Executive Officer
- Christopher GarabedianDirector
Patents
- Tetrahydropyrazolopyridine-analog Ligands Of NLRX1 And Uses Thereofapplication
- NLRX1 Ligandsapplication
- Substituted 1,6-DIHYDROPYRIDINES As PLXDC2 Ligandsapplication
- NLRX1 Ligandsgranted
- NLRX1 Ligandsapplication
- Substituted Imidazoles As PLXDC2 Ligandsgranted
- Lanthionine Synthetase C-like 2-BASED Therapeuticsgranted
- NLRX1 Ligandsgranted
- Crystalline Forms Of PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE)granted
- Lancl Ligandsgranted
- Lanthionine C-like Protein 2 Ligands, Cells Prepared Therewith, And Therapies Using Samegranted
- Therapies With Lanthionine C-like Protein 2 Ligands And Cells Prepared Therewithgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.